bluuebunny/crossref_metadata_2025_split huggingface dataset:
mapMECFS: a portal to enhance data discovery across biological disciplines and collaborative sites
Authors: Mathur Ravi , Carnes Megan U. , Harding Alexander , Moore Amy , Thomas Ian , Giarrocco Alex , Long Michael , Underwood Marcia , Townsend Christopher , Ruiz-Esparza Roman , Barnette Quinn , Brown Linda Morris , Schu Matthew 
Published: May 2021

Abstract
Background

Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a debilitating disease which involves multiple body systems (e.g., immune, nervous, digestive, circulatory) and research domains (e.g., immunology, metabolomics, the gut microbiome, genomics, neurology). Despite several decades of research, there are no established ME/CFS biomarkers available to diagnose and treat ME/CFS. Sharing data and integrating findings across these domains is essential to advance understanding of this complex disease by revealing diagnostic biomarkers and facilitating discovery of novel effective therapies.
Methods

The National Institutes of Health funded the development of a data sharing portal to support collaborative efforts among an initial group of three funded research centers. This was subsequently expanded to include the global ME/CFS research community. Using the open-source comprehensive knowledge archive network (CKAN) framework as the base, the ME/CFS Data Management and Coordinating Center developed targeted metadata collection, smart search capabilities, and domain-agnostic data integration to support data findability and reusability while reducing the barriers to sustainable data sharing.
Results

We designed the mapMECFS data portal to facilitate data sharing and integration by allowing ME/CFS researchers to browse, share, compare, and download molecular datasets from within one data repository. At the time of publication, mapMECFS contains data curated from public data repositories, peer-reviewed publications, and current ME/CFS network researchers.
Conclusions

mapMECFS is a disease-specific data portal to improve data sharing and collaboration among ME/CFS researchers around the world. mapMECFS is accessible to the broader research community with registration. Further development is ongoing to include novel systems biology and data integration methods.
Overlap of functional dyspepsia and irritable bowel syndrome by revised Rome IV criteria: meta-analysis
Authors: Maev I. V. , Umyarova R. M. , Andreev D. N. , Vyuchnova E. S. , Lebedeva E. G. , Dicheva D. T. , Borzova D. V. 
Published: May 2021

Introduction. Functional dyspepsia (FD) and irritable bowel syndrome (IBS) overlap is an adverse clinical situation, as patients with this syndrome have more severe clinical manifestations resulting in significant reductions in quality of life. For now, there are no meta-analytical papers that would summarize the frequency of FD – IBS overlap using the revised Rome IV criteria. Objective. To organize data on the prevalence of FD – IBS overlap using the revised Rome IV criteria.Materials and methods. A search for studies was conducted in MEDLINE / PubMed, EMBASE, Cochrane electronic databases. The search depth was 6 years (from January 2016 to February 2021). The final analysis included original publications from peerreviewed periodicals that used the revised Rome IV criteria as a method for diagnosing FD and IBS in the adult population with detailed descriptive statistics allowing to include resulting data in the meta-analysis.Results and discussion. The final analysis included 6 studies involving 1,180 patients with PD and 600 patients with IBS. The generalized prevalence of IBS in patients with PD was 41.511% (95% CI: 22.203–62.288). The analysis was undertaken by using a random-effects model, as there was significant heterogeneity among results (p < 0.0001; I2 = 94.28%). The generalized prevalence of PD in patients with IBS was 38.791% (95% CI: 9.438–73.710). The analysis was undertaken by using a random-effects model, as there was significant heterogeneity among results (p < 0.0001; I2 = 99.25%).Сonclusion. The complete meta-analysis showed that the frequency of FD - IBS overlap using the revised Rome IV criteria is quite high and accounts for about 40%. At the same time, further large studies of more homogeneous structure are needed to verify these results and study the potential pathogenetic relationship between PD and IBS.
Comparative efficacy and safety of chimeric and recombinant anti-TNF-α mAbs
Authors: Drozdov V. N. , Shikh E. V. , Astapovskiy A. A. , Serebrova S. Yu. , Starodubtsev A. K. 
Published: May 2021

TNF-α has been known since 1985. It is a multifunctional proinflammatory cytokine, synthesized mainly by monocytes and macrophages. Since its discovery, many studies have been conducted that have proven that it provides homeostatic function and regulates many biological processes in the body. Violation of its regulation in humans is associated with the development of many autoimmune diseases. The intensive studies that led to the understanding of its polyfunctionality and its role in the immunopathogenesis of a number of diseases served as the basis for the development of anti-cytokine therapy with monoclonal antibodies. In 1975, a technique for producing such antibodies was developed. The first antibodies against TNF-α obtained were chimeric, consisting of 30% mouse protein. Because of this feature, drugs based on chimeric antibodies had immunogenicity, which was manifested in the formation of antibodies to the drug, which led to a decrease in their effectiveness. To reduce immunogenicity, scientists in 1990 created the first fully human monoclonal antibody based on a technology called phage display. This is how adalimumab was born, the first fully human multi-clonal antibody to TNF-α. Humira® (adalimumab) is currently considered a widely studied drug from the group of TNF-α inhibitors, with a good safety and efficacy profile. The article presents current data that demonstrate that the drug significantly improves the course of diseases such as rheumatoid and psoriatic arthritis, and will allow for long-term remission in Crohn’s disease.
How to improve effectiveness of treatment of patients with irritable bowel syndrome?
Authors: Golovanova E. V. 
Published: May 2021

This article discusses ways to improve the effectiveness of treatment of irritable bowel syndrome (IBS), one of the most common functional gastrointestinal disorders (FGID). The significance of this issue is caused by high frequency of pathology detection among the young employable population and the difficulties in choosing an effective treatment that relieves not only the symptom severity, but also the frequency of relapses. Inadequate therapy reduces patients’ compliance with treatment and significantly worsens their quality of life. The choice of a drug that fails to provide a positive effect on all factors that form the pain syndrome is the most common reason for ineffective treatment. In addition, the measures aimed at managing such pathogenic factors as intestinal microbiota dysbiosis are often not taken. Meanwhile, numerous studies have shown that the intestinal microbiota imbalance is accompanied by increased intestinal permeability, which leads to the penetration of aggressive agents through extended intercellular spaces. This is accompanied by the occurrence of subclinical inflammation in the submucosal layer, which results in impaired motor function and increased visceral sensitivity. Thus, the intestinal microflora imbalance is one of the most important factors that form clinical symptoms of IBS. The article substantiates the advantages of using trimebutin, a gastrointestinal tract motility regulator, in functional gastrointestinal diseases from the standpoint of evidence-based medicine. The modern scientific knowledge on the effectiveness of microbiota adjustment in alleviating IBS symptoms is presented. In particular, the double-blind, placebo-controlled study has shown the efficacy of a multi-strain probiotic complex in relieving clinical symptom severity of IBS. The optimal treatment regimen for a patient with IBS should include a drug regulating the gastrointestinal motility and reducing visceral hypersensitivity and a probiotic complex containing bacterial strains that have proved their efficacy in this group of patients.
Patient with constipation syndrome at the ambulatory-polyclinic reception: actual aspects of differential diagnosis and treatment
Authors: Trukhan D. I. , Degovtsov E. N. , Drokina O. V. 
Published: May 2021

Constipation is a serious medical and social problem due to the widespread prevalence of this condition, a decrease in the quality of life and social activity of patients. For the successful treatment of constipation, it is necessary to establish the causes leading to the violation of the stool in the patient. And this task is a priority for the doctor at the outpatient stage.The clinical features of constipation largely depend on their cause, duration, severity and characteristics of intestinal damage. Constipation is often accompanied by general somatic and other gastroenterological symptoms.Within the framework of the review article, the main conditions and diseases are considered, in the clinical picture of which there is constipation syndrome, which must be considered by the doctor at the outpatient stage when conducting differential diagnosis and prescribing appropriate treatment, which also presupposes impact on causal factors. Currently, drugs based on high molecular weight polyethylene glycol 4000 are widely used to treat chronic constipation in adults and children in most countries of the world. Preparations based on polyethylene glycol 4000 are affordable and easy to use, they can be used both on an outpatient basis and in a hospital. Polyethylene glycol 4000 preparations act quickly, are highly effective and well tolerated, have a high safety profile (practically does not affect homeostasis) both for adult patients and in pediatric practice. International clinical trials have shown the possibility of long-term use of polyethylene glycol 4000 preparations.Current international clinical guidelines and domestic clinical guidelines for the treatment of constipation recommend the use of polyethylene glycol 4000 preparations instead of lactulose and volume-forming laxatives in the symptomatic treatment of constipation in children and adults. In the second part of the review, the possibilities of polyethylene glycol 4000 and the first domestic drug polyethylene glycol 4000 in the treatment of chronic constipation are considered.
The importance of functional diagnostics in determining the cause of antisecretary therapy inefficiency in a patient with heartburn: clinical observation
Authors: Barkalova E. V. , Andreev D. N. , Ovsepian M. A. 
Published: May 2021

One of the main symptoms of gastroesophageal reflux disease is heartburn, for the relief of which proton pump inhibitors are traditionally prescribed. However, there are frequent cases of heartburn, refractory to antisecretory therapy, when there is no complete relief of the symptom or only a partial clinical effect. The reason for an unsatisfactory response may be the functional genesis of heartburn. The purpose of the presented clinical observation is to demonstrate the heterogeneity of patients with heartburn, the role of functional research methods in the differential diagnosis of various conditions that accompany this symptom. A 42-year-old patient was admitted for an additional clinical examination with complaints of heartburn refractory to antisecretory therapy, which included high-resolution esophageal manometry, 24-hours pH-impedance. The manometric assessment of the structure and function of the lower esophageal sphincter, as well as the contractility of the thoracic esophagus, revealed no violations. The data of 24-hours pH-impedance demonstrated the absence of pathological reflux and the association of active symptoms with refluxes, which determined the functional nature of heartburn and explained the ineffectiveness of treatment with proton pump inhibitors. Heartburn can be functional in nature and significantly reduce the quality of life of patients. Functional heartburn requires different management tactics from gastroesophageal reflux disease, which is based on an adequate differential diagnosis, including functional research methods such as high-resolution esophageal manometry and 24-hours pH-impedance measurement, which allow to exclude other conditions accompanied by similar symptoms.
Obesity, non-alcoholic fatty liver disease, COVID-19: dangerous liaisons
Authors: Tikhonov S. V. , Dekkanova V. D. , Vinnichuk S. A. , Fil T. S. , Bakulina N. V. 
Published: May 2021

The pandemic of COVID-19 is changing the usual clinical practice. Most of the drugs used for the etiotropic and pathogenetic therapy of COVID-19 do not have a sufficient evidence base, approaches to therapy of liver, gastrointestinal tract and other body systems damage in the structure of COVID-19 and post COVID-19 syndrome are under development. Coronavirus infection is more severe in obese patients with associated diseases; the liver plays an important role in this process. Retrospective analysis of the medical histories of patients with a new coronavirus infection hospitalized in the clinic of North-Western State Medical University named after I.I. Mechnikov identified that 34.7% of patients were overweight, 51.3% obese, 77% abdominal obesity (alanine aminotransferase (ALAT) was on average 76.2 ± 58.8 U/L, aspartate aminotransferase (ACAT) 60.7 ± 48.6 U/L). At the time of hospitalization, increased transaminases was detected in 71% of patients and correlated with markers of the severe course of COVID-19 (the level of C-reactive protein, ferritin, % of blood oxygen saturation). In patients with severe new coronavirus infection, receiving therapy with JAK-kinase inhibitors and/or biological drugs, often was a significant increase of ALAT and ASAT up to 5–10 upper limits of the norm. In the process of histological examination of the liver tissue of patients who died of extremely severe course of infection, characteristic fatty degeneration of hepatocytes was revealed. Therapy with a multicomponent drug containing inosine, meglumine, methionine, nicotinamide and succinic acid contributed to a dynamic decrease of transaminases and an improvement in the course of the new coronavirus infection.
The role of Staphylococcus aureus in the course of polyposis sinusitis
Authors: Turovski A. B. , Bondareva G. P. , Musaev K. M. 
Published: May 2021

Introduction. Today, there are lot of theories of pathogenesis of polypoid sinusitis. The contribution of Starchylocossus aureus (S. aureus) to the occurrence of this pathogenetic reaction is being actively discussed.Objective: to improve the effectiveness of treatment of polypoid sinusitis using the results of the study of the effect of persistent staphylococcal infection on the onset and course of the disease.Materials and methods. The authors examined 105 patients with recurrent polyposis sinusitis aged 20 to 65 years. All patients underwent FESS surgery for recurrent polypous sinusitis at the initial visit. In the postoperative period, all patients received treatment according to one of two schemes. The first scheme included antihistamines and topical steroids, the second additionally included clarithromycin. The patients underwent bacteriological examination of smears for flora and fungi from the cavity; cytological examination of smears-prints from the mucous membrane of the nasal cavity (we counted neutrophils, eosinophils and lymphocytes in the preparation); immunological and allergic examination (skin tests, serum specific IgE levels).Results and discussion. It has been established that the presence of a carriage and sensitization to S. aureus in a patient, especially in combination with atopy, results in a more severe course of polyposis sinusitis severe nasal obstruction (91% versus 69.5%, respectively) and is characterized by more pronounced eosinophilic inflammation than Polypoid Sinusitis associated with infection with other microorganisms (the number of eosinophils in the blood: 7.5% and 4.3%, respectively; the level of eosinophils in smears from the nasal mucosa is 13 and 4.8%, respectively; the average ECP level is 17.6 and 8.1 ug / ml, respectively).Conclusions. The use of topical GCS remains one of the leading methods for preventing recurrence of PS. However, in addition to the backbone therapy with topical GCS and antihistamines, it is advisable to complete a course of antibiotics during nasal colonization with S. aureus.
A reusable chitosan/TiO2@g-C3N4 nanocomposite membrane for photocatalytic removal of multiple toxic water pollutants under visible light
Authors: Xu Shengnan , Xiao Gang , Wang Zishuai , Wang Yaoqiang , Liu Ziwei , Su Haijia 
Published: May 2021

Abstract
Photocatalysis has been proved to be a promising approach in wastewater purification. However, it is hard to recycle powdery photocatalysts from wastewater in industry, but immobilizing them using larger materials can overcome this drawback. For that reason, TiO2@g-C3N4 was embedded into chitosan to synthesize a highly reusable and visible-light-driven chitosan/TiO2@g-C3N4 nanocomposite membrane (CTGM). CTGM showed enhanced photoactivity and the photocatalytic efficiencies of the toxic water pollutants methyl orange (M.O.), rhodamine B (Rh.B), chromium (VI) (Cr (VI)), 2,4-dichlorophenol (2,4-DCP) and atrazine (ATZ) were more than 90% under visible light at ambient conditions. Significantly, CTGM was easy to recycle and showed excellent reusability: there was no decrease in the photocatalytic decolorization efficiency of Rh.B throughout 10 cycles. A continuous-flow photocatalysis system was set up and 90% of Rh.B was effectively decolorized. A simple approach was developed to prepare a novel, effective and visible-light-driven membrane that was easy to reuse, and a feasible photocatalysis continuous-flow system was designed to be a reference for wastewater treatment in industry.
Troika's Portuguese Ministry of Justice Experiment: Dissipation of Doubts about Success, Continuation and Confirmation of Positive Results
Authors: Alves Ribeiro Correia Pedro Miguel , Videira Susana Antas , De Oliveira Mendes Ireneu 
Published: May 2021

Abstract
This article is the continuation of a series of studies on the impact of the measures implemented by the Portuguese Ministry of Justice. This research addresses the results obtained in the civil enforcement actions arising from objectives included in the Memorandum of Understanding (MoU) signed between Portugal and the so-called Troika (International Monetary Fund / European Commission / European Central Bank). The empirical study was extended to cover the quantitative analysis of the results achieved not only during the Troika period but also during the post-Troika period. The results show and confirm a continued positive effect on the level of civil enforcement actions in the period analyzed.
Keywords: Troika, Memorandum of Understanding, Portuguese Ministry of Justice, Civil Enforcement Actions, Evaluation of Public Policies.
Resumen
Este arti?culo es la continuidad de una serie de estudios sobre el impacto de las medidas implementadas por el Ministro de la Justicia Portuguesa. Esta investigacio?n se acerca a los resultados obtenidos en las medidas de ejecucio?n que salieron a la luz de los objetivos incluidos en el Memora?ndum de Entendimiento (MoU) firmado entre Portugal y la llamada Troika (Fondo Monetario Internacional/Comisio?n Europea/Banco Central Europeo). El estudio empi?rico fue ampliado para cubrir los ana?lisis cuantitativos de los resultados obtenidos no solamente durante la Troika, pero en el periodo post-Troika. Los resultados confirman la continuacio?n del efecto positivo en el nivel de las acciones de las medidas de ejecucio?n en el periodo analizado.
Palabras Clave: Troika, Memora?ndum de Entendimiento, Ministro de la Justicia Portuguesa, Civil, Medidas de Ejecucio?n, Evaluacio?n de poli?ticas pu?blicas.

Resumo
Este artigo e? a continuac?a?o de uma se?rie de estudos sobre o impacto das medidas implementadas pelo Ministro da Justic?a Portuguesa. Esta pesquisa caminha em direc?a?o aos resultados obtidos nas medidas de execuc?a?o que surgiram dos objetivos inclui?dos no Memorando de Entendimento (Acordo) (MoU) assinado entre Portugal e a chamada Troika (Fundo Moneta?rio Internacional/Comissa?o Europeia/ Banco Central Europeu). O estudo empi?rico foi ampliado para cobrir as ana?lises quantitativas dos resultados obtidos na?o somente durante a Troika, mas tambe?m no peri?odo po?s-Troika. Os resultados confirmam a continuidade do efeito positivo no ni?vel das ac?o?es das medidas de execuc?a?o no peri?odo analisado.
Palavras-chave: Troika, Memorando de Entendimento (Acordo), Ministro da Justic?a Portuguesa, Civil, Medidas de Execuc?a?o, Avaliac?a?o de poli?ticas pu?blicas.
SYNTHESIS AND CHARACTERIZATION OF STARCH MALONATE: DEVELOPMENT OF FAST DISSOLVING TABLETS OF ACECLOFENAC BY 23 FACTORIAL DESIGNS
Authors: KUMARI ANNU , KUMAR R. SANTOSH 
Published: May 2021

Objective: The aim of the research work is to develop a new superdisintegrant (starch malonate) which can help in enhancing the solubility and drug dissolution of poorly soluble drugs. Hence, starch malonate (new superdisintegrant) was prepared and has been evaluated for its superdisintegrant property by incorporating it into fast dissolving tablets of Aceclofenac.
Methods: Superdisintegrant was developed by using esterification reaction. Prepared starch malonate was then subjected for different characterization tests (solubility, pH, melting point, swelling index, FTIR, DSC studies. 23 factorial design method was used to formulate fast dissolving tablets of aceclofenac employing starch malonate. Two known superdisintegrants croscarmellose sodium and crospovidone have been used along with starch malonate in combinations to develop fast dissolving tablets. Prepared tablets were then subjected to different tests for tablets like hardness, friability, disintegration time, dissolution studies. A stability study was performed to determine the stability of the formulation. Design expert study was conducted to know the interaction between different superdisintegrants and to select best optimized formulation in among all formulations.
Results: Starch malonate prepared was found to be fine, free flowing slightly crystalline powder, insoluble in aqueous and organic solvents. Tablets of all formulations were of excellent quality concerning drug content (100±5%), hardness (3.8-4.2 kg/cm2), and friability (less than 0.15%). In all formulations, formulation F2 found to be optimized formulation with least disintegration time 38 S, less wetting time 17±0.08 s and enhanced percent dissolved rate in 5 min i.e., 99.84% as compared to other formulations.
Conclusion: From this it was concluded that starch malonate can be used as a novel superdisintegrant to enhance the drug dissolution of poorly soluble drugs. Optimized formulation F2 showed enhanced drug dissolution at 5% concentration as compared to other formulation and showed least disintegration time and enhanced drug dissolution as compared to other formulations and pure drug.